Currently, it is not known whether metastatic prostate cancer patients have significant clinical benefit from NaF-imaging e.g., in case of oligometastatic disease or in cases of false-positive rib findings commonly occurring in PSMA imaging. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.